WallStreetZenWallStreetZen

NASDAQ: CING
Cingulate Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CING

Based on 2 analysts offering 12 month price targets for Cingulate Inc

Min Forecast
$14.00+167.69%
Avg Forecast
$34.50+559.66%
Max Forecast
$55.00+951.63%

Should I buy or sell CING stock?

Based on 2 analysts offering ratings for Cingulate Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CING's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CING as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CING stock forecasts and price targets.

CING stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-08
lockedlocked$00.00+00.00%2026-03-23

1 of 1

Forecast return on equity

Is CING forecast to generate an efficient return?

Company
N/A
Industry
73.34%
Market
162.36%

Forecast return on assets

Is CING forecast to generate an efficient return on assets?

Company
N/A
Industry
30.38%

CING earnings per share forecast

What is CING's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.69
Avg 2 year Forecast
-$1.17
Avg 3 year Forecast
-$0.57

CING revenue forecast

What is CING's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$8.3M
Avg 3 year Forecast
$34.1M

CING vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CING$5.23$34.50+559.66%Strong Buy
GRML$0.50N/AN/A
OKYO$1.62$6.00+270.37%Strong Buy
BYSI$1.42N/AN/A
PDSB$1.14$9.00+689.47%Strong Buy
View Top Biotech Stocks

Cingulate Stock Forecast FAQ

Is Cingulate Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CING) stock is to Strong Buy CING stock.

Out of 2 analysts, 1 (50%) are recommending CING as a Strong Buy, 1 (50%) are recommending CING as a Buy, 0 (0%) are recommending CING as a Hold, 0 (0%) are recommending CING as a Sell, and 0 (0%) are recommending CING as a Strong Sell.

If you're new to stock investing, here's how to buy Cingulate stock.

What is CING's earnings growth forecast for 2026-2028?

(NASDAQ: CING) Cingulate's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.

Cingulate's earnings in 2026 is -$22,449,911.On average, 7 Wall Street analysts forecast CING's earnings for 2026 to be -$19,689,568, with the lowest CING earnings forecast at -$24,045,646, and the highest CING earnings forecast at -$17,460,362. On average, 6 Wall Street analysts forecast CING's earnings for 2027 to be -$13,581,057, with the lowest CING earnings forecast at -$17,663,863, and the highest CING earnings forecast at -$5,128,218.

In 2028, CING is forecast to generate -$6,642,264 in earnings, with the lowest earnings forecast at -$6,381,783 and the highest earnings forecast at -$6,837,624.

What is CING's revenue growth forecast for 2026-2028?

(NASDAQ: CING) Cingulate's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.05%.

Cingulate's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast CING's revenue for 2026 to be $0, with the lowest CING revenue forecast at $0, and the highest CING revenue forecast at $0. On average, 6 Wall Street analysts forecast CING's revenue for 2027 to be $96,424,459, with the lowest CING revenue forecast at $34,188,122, and the highest CING revenue forecast at $197,500,363.

In 2028, CING is forecast to generate $396,838,047 in revenue, with the lowest revenue forecast at $239,468,028 and the highest revenue forecast at $560,441,004.

What is CING's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CING) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 30.38%.

What is CING's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CING price target, the average CING price target is $34.50, with the highest CING stock price forecast at $55.00 and the lowest CING stock price forecast at $14.00.

On average, Wall Street analysts predict that Cingulate's share price could reach $34.50 by Apr 8, 2027. The average Cingulate stock price prediction forecasts a potential upside of 559.66% from the current CING share price of $5.23.

What is CING's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CING) Cingulate's current Earnings Per Share (EPS) is -$4.44. On average, analysts forecast that CING's EPS will be -$1.69 for 2026, with the lowest EPS forecast at -$2.07, and the highest EPS forecast at -$1.50. On average, analysts forecast that CING's EPS will be -$1.17 for 2027, with the lowest EPS forecast at -$1.52, and the highest EPS forecast at -$0.44. In 2028, CING's EPS is forecast to hit -$0.57 (min: -$0.55, max: -$0.59).

What is CING's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CING) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.